Canada''s drug price watchdog reaches agreement with drug-maker on reporting requirements for leukemia drug
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 11/03/16 -- Patented Medicine Prices Review Board
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on October 28, 2016 requiring that Baxalta Canada Corporation (Baxalta) provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations. The Order relates to the medicine Oncaspar, which is sold in Canada under Health Canada''s Special Access Programme and is used in the treatment of patients with Acute Lymphoblastic Leukemia.
Baxalta agreed to provide the information sought by the PMPRB for the period commencing July 1, 2015, when Baxalta began selling Oncaspar in Canada.
The Hearing Panel''s Order resolved this matter and, as such, no hearing will be held in November 2016.
Quick Facts
Related Documents
- Board Order ()
Associated Links
- (Justice Canada)
- (Justice Canada)
- (Patented Medicine Prices Review Board)
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2016 - 12:15 Uhr
Sprache: Deutsch
News-ID 1467909
Anzahl Zeichen: 2282
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 358 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Canada''s drug price watchdog reaches agreement with drug-maker on reporting requirements for leukemia drug
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
